by Clinical Neuropsychologist | Friday, April 5, 2024 | Dementia
Abstract INTRODUCTION To support clinical trial designs focused on early interventions, our study determined reliable early amyloid-β (Aβ) accumulation based on Centiloids (CL) in pre-dementia populations. METHODS A total of 1032 participants from the Amyloid Imaging...
by Clinical Neuropsychologist | Thursday, April 4, 2024 | Dementia
Abstract INTRODUCTION Emerging evidence links changes in the gut microbiome to late-onset Alzheimer’s disease (LOAD), necessitating examination of AD mouse models with consideration of the microbiome. METHODS We used shotgun metagenomics and untargeted...
by Clinical Neuropsychologist | Thursday, April 4, 2024 | Dementia
Abstract INTRODUCTION Screening for Alzheimer’s disease neuropathologic change (ADNC) in individuals with atypical presentations is challenging but essential for clinical management. We trained automatic speech-based classifiers to distinguish frontotemporal...
by Clinical Neuropsychologist | Wednesday, April 3, 2024 | Dementia
Dementia, Volume 23, Issue 4, Page 525-549, May 2024. BackgroundDementia disproportionately affects women including persons living with dementia and caregivers. Person-centered care, rather than disease-focused, is recommended to improve care for affected persons...
by Clinical Neuropsychologist | Wednesday, April 3, 2024 | Dementia
Abstract INTRODUCTION Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer’s disease (AD). METHODS PRIME was a Phase 1b, double-blind, randomized clinical trial of aducanumab. During the 12-month...
by Clinical Neuropsychologist | Tuesday, April 2, 2024 | Dementia
Abstract INTRODUCTION Genome-wide association studies have identified numerous disease susceptibility loci (DSLs) for Alzheimer’s disease (AD). However, only a limited number of studies have investigated the dependence of the genetic effect size of established...
